SHINE Technologies and Nucleus RadioPharma are partnering to advance radioligand cancer treatments, SHINE announced recently.

“We are proud to partner with Nucleus RadioPharma to supply the high-purity lutetium-177 that powers their innovative radioligand therapy,” SHINE Technologies Chief Commercial Officer of Isotopes Harrie Buurlage said in a statement. “This agreement demonstrates our ability to produce critical medical isotopes at commercial scale to enable new treatments that can improve patients’ lives.”

According to a release, SHINE will provide lutetium-177 to Nucleus RadioPharma’s radioligand therapy (RLT) offerings for targeted radiopharmaceutical treatments for neuroendocrine tumors and prostate cancer.

Financial details of the partnership were not disclosed.